ABSTRACT
The complexity of the mammalian p53 pathway and protein kinase C (PKC)
family has hampered the discrimination of the effect of PKC isoforms on p53 activity.
Using yeast co-expressing the human wild-type p53 and a mammalian PKC−α, −δ, −ε or −ζ, we showed a differential regulation of p53 activity and phosphorylation state by PKC isoforms. Whereas PKC-α reduced the p53-induced yeast growth inhibition and cell cycle arrest, PKC−δ, −ε enhanced the p53 activity through p53 phosphorylation, and PKC−ζ had no effect on p53. This work identified positive and negative p53 regulators which represent promising pharmacological targets in anti-cancer therapy.
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INTRODUCTION
The p53 tumour suppressor protein is mutated in about half of all human tumours and in many others that retain a wild-type (WT) p53, p53-dependent pathways leading to cell cycle arrest or cell death are often deficient. Restoring p53 function represents therefore a promising approach for cancer therapeutics. Among the different mechanisms of p53 regulation, post-translational modification by phosphorylation has been shown to play a critical role in the stabilization and activation of WT p53 (1).
One of the key enzymes involved in p53 phosphorylation is protein kinase C (PKC) (2, 3) . PKC is a family of serine/threonine kinases with at least 10 isoforms grouped into three subfamilies based on their primary structure and cofactors required for activation: classical (α, βI, βII and γ), novel (δ, ε, η and θ) and atypical (ζ and λ/ι). PKC isoforms are important regulators of several cellular processes, such as cell proliferation and death, and a striking feature is that individual isoforms can exert either similar or opposite effects in these processes (4, 5) .
Due to the high complexity of the mammalian p53 pathway and PKC family, 
diseases (6). Since the yeast PKC (Pkc1p in
Saccharomyces cerevisiae) is a structural but not a functional homologue of mammalian PKC isoforms, yeast was considered a well-suited organism to study individual mammalian PKC isoforms (7) . Indeed, the yeast PKC assay has been used by us to search for isoform-selective PKC modulators (8) and to study the regulation of human apoptotic proteins by PKC isoforms (9) . Similarly, though no orthologues of human p53
have been identified in yeast, S. cerevisiae has been extensively used to score several functional properties of human p53 (10).
The yeast expression systems established in this study allowed investigating the existence in yeast of a molecular mechanism underlying the regulation of cell proliferation through specific PKC isoforms and WT p53. The results obtained underscore a differential regulation of p53 activity by PKC isoforms with the identification of kinases responsible for both a positive and negative regulation of p53.
MATERIAL AND METHODS

Plasmids
Constructed 
Effect of the selective PKC inhibitor Ro 32-0432 on yeast growth
To 
Cell death markers
Plasma membrane integrity and DNA fragmentation were analysed by fluorescence microscopy using propidium iodide (PI) and In Situ Cell Death Detection Kit, Fluorescein, respectively, whereas yeast metacaspase (Yca1p) activation and reactive oxygen species (ROS) accumulation were analysed by flow cytometry using FITC-VADfmk and dihydroethidium (DHE), respectively, as described (8).
Cell cycle
Flow cytometric analysis of DNA content was performed using Sytox Green Nucleic Acid, as described (8) . Yeast cell cycle phases were identified and quantified using ModFit LT software (Verity Software House Inc., Topsham, USA).
Western blot
For human WT p53 and mammalian PKC isoforms detection, anti-p53 (DO-1) and anti-PKC−α/PKC−δ/PKC−ε/PKC−ζ mouse monoclonal antibodies (Santa Cruz Biotechnology) were used. p53 phosphorylation was analysed using phospho-p53(Ser15) mouse monoclonal antibody, phospho-p53(Ser20) and phosphop53( Ser46) rabbit polyclonal antibodies (Cell Signalling Technology), and PAb421 mouse monoclonal antibody (Calbiochem). The etoposite-treated MCF7 cell lysate (sc-2281; Santa Cruz Biotechnology) was used as positive control. Immunoblots were developed by enhanced chemiluminescence, as described (9) . Band intensities were quantified using Bio-Profil Bio-1D++ software.
Statistical analysis
Data were analysed statistically using SigmaStat 3.5 programme. Differences between means were tested for significance using the unpaired Student's t-test (P < 0.05).
RESULTS
Differential regulation of WT p53-induced yeast growth inhibition by PKC isoforms
In accordance with other authors (11, 12) , we verified that expression of human WT p53 in S. cerevisiae inhibited cell growth (Fig. 2.1A,B) . Instead, and as previously reported by us (8, 9) , in our experimental conditions expression of a mammalian PKC isoform did not significantly interfere with yeast growth (Fig. 2.1A,B) . However, when PKC−α, −δ, −ε or −ζ was co-expressed with p53, a differential regulation of p53-induced growth inhibition by PKC isoforms was obtained ( Fig. 2.1A,B) . This was particularly evident for 45 hours incubation ( Fig. 2.1B ). For this time, whereas PKC−α significantly reduced the p53-induced growth inhibition, PKC−δ and −ε significantly increased the p53 growth-inhibitory effect and PKC−ζ did not interfere with the p53 effect.
The direct effect of PKC isoforms on p53 was evidenced using the selective PKC inhibitor Ro 32-0432. Though 1 µM Ro 32-0432 did not significantly interfere with the growth of yeast expressing p53 or a PKC isoform only, it significantly reduced the effects exhibited by PKC−α, −δ and −ε on p53 activity (Fig. 2.1C ).
As confirmed by Western blot analysis, this distinct influence of each PKC isoform on p53 effect was not a consequence of significant changes in the expression levels of p53 or a PKC isoform in yeast co-expressing both proteins ( Fig. 2.2 ).
WT p53 yeast growth-inhibitory effect and its stimulation by PKC−δ and −ε are not associated with cell death
A recent work associated the human WT p53 growth-inhibitory effect to the induction of an apoptotic cell death in S. cerevisiae (11) . Hence, typical necrotic and apoptotic markers, as loss of plasma membrane integrity, DNA fragmentation, ROS accumulation and Yca1p activation, were investigated.
However, in our experimental conditions, expression of human WT p53 in yeast did not significantly increase the PI and TUNEL positive cells (Fig. 2.3A,B) , Yca1p activation and ROS levels ( Fig. 2.3C,D) . Even in the presence of a PKC isoform, particularly PKC−δ or −ε, characteristic features of cell death were not detected ( Fig.   2.3B-D) . Indeed, though yeast co-expressing p53 and PKC−ε presented a significant increase in ROS levels, this was not accompanied by an increase of PI and TUNEL positive cells and Yca1p activation (Fig. 2.3B-D) . However, considerable levels of p53 expression were also achieved in our work using a pLS89 centromeric vector (Fig. 2.2A,B) . Additionally, a minimal medium similar to that described by Amor et al. (11) 
WT p53 yeast growth-inhibitory effect is associated with S-phase cell cycle arrest that is differently regulated by PKC isoforms
As in mammalian cells, where p53 controls cell cycle mainly through the G1/S checkpoint (2), we detected that p53-induced yeast growth inhibition was associated with S-phase cell cycle arrest (Fig. 2.4) . Instead, and in agreement with the absence of effect on yeast growth, PKC isoforms only slightly interfered with the yeast cell cycle progression (Fig. 2.4) . However, when PKC−α, −δ, −ε or −ζ was co-expressed with p53, a specific PKC isoform-dependent modulation of cell cycle through p53 was obtained (Fig. 2.4) . 
Differential regulation of p53 effects by PKC isoforms is associated with distinct patterns of p53 phosphorylation in yeast
Phosphorylation of WT p53 at commonly reported p53 phosphorylation sites, Ser15, Ser20, Ser46 and Ser376-378 (2, 3, 14) , was checked by Western blot analysis. p53 phosphorylation at Ser15, Ser20 and Ser46, analysed using a phospho-p53 antibody specific for each serine, was not detected neither in yeast expressing p53 only nor in yeast co-expressing p53 and a PKC isoform (Fig. 2.5A-C) . p53 phosphorylation at Ser376-378 was analysed using the PAb421 antibody which preferentially recognises unphosphorylated p53 residues at Ser376-378. Indeed, it was demonstrated that when p53 was phosphorylated at Ser376-378 by PKC the PAb421 band almost disappeared (3). In our case, a high intensity PAb421 band was obtained for yeast expressing p53 only (Fig. 2.5D,E) , indicating the absence of p53 phosphorylation at Ser376-378 by endogenous yeast kinases. This band was therefore used as control.
Interesting, when compared to control band, whereas PKC−α slightly decreased and PKC−ζ did not interfere with the PAb421 band intensity, PKC−δ and −ε markedly decreased the intensity of this band (Fig. 2.5D,E) . This indicated that, while PKC−α and −ζ did not significantly interfere with the degree of p53 phosphorylation, PKC−δ and −ε markedly increased p53 phosphorylation.
Overall, despite phosphorylation of human WT p53 by endogenous kinases was already reported for S. cerevisiae (12) , to our knowledge the sites of p53 phosphorylation were still unclear. The results obtained indicated that p53 is not phosphorylated at Ser15, Ser20, Ser46 and Ser376-378 by yeast kinases. Importantly, though p53 phosphorylation by PKC has been described at distinct serine residues (2, 3, 14) , in yeast we only detected phosphorylation at Ser376-378, which is the most commonly reported PKC phosphorylation site in mammalian cells (2, 3) . For this p53 residue, a PKC isoformdependent phosphorylation pattern was identified.
DISCUSSION
The involvement of PKC family in the regulation of cell proliferation was early recognised. While PKC−α and −ζ are frequently associated to the proliferation of human cancers and PKC−δ is often linked to an anti-proliferative effect (4, 5) , PKC−ε has been associated both to proliferative (4, 5) and anti-proliferative (15) 
ABSTRACT
The role of individual protein kinase C (PKC) isoforms in the regulation of p53-mediated apoptosis is still uncertain. Using yeast cells co-expressing the human wild-type p53 and a single mammalian PKCα, δ, ε or ζ, we showed a differential regulation of p53-mediated apoptosis by these PKC isoforms. Whereas PKCα and ζ had no effect on p53 activity, PKCδ and ε stimulated a p53-mediated mitochondria-dependent apoptosis.
Moreover, using pifithrin-α and -µ, selective inhibitors of p53 transcriptional activity and mitochondrial p53 translocation, respectively, we showed the activation of a transcriptiondependent and -independent p53-mediated apoptosis by PKCδ and ε. The activation of mitochondrial p53 translocation by PKCδ and ε was further confirmed by immunofluorescence and Western blot analysis.
Together, this work reveals the conservation in yeast of functional transcriptiondependent and -independent p53 apoptotic mechanisms. Furthermore, it gives mechanistic insights about the regulation of p53-mediated apoptosis by PKCδ and ε through modulation of p53 transcriptional activity and of its translocation to mitochondria.
Finally, it underscores a major role of PKCδ and ε as positive regulators of p53-mediated apoptosis, and therefore as promising therapeutic targets in cancer.
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INTRODUCTION
The major tumour suppressor protein, p53, is a sequence-specific transcription factor that determines the fate of a cell. p53 regulates the expression of an assortment of genes involved in cell cycle regulation, apoptosis and numerous other processes. In large part, the potent tumour suppressing function of p53 has been attributed to its ability to induce apoptosis. Despite the prominence of p53 nuclear transcriptional activity in the induction of apoptosis, a transcription-independent mechanism involving mitochondrial p53 translocation, is receiving increasing attention. Indeed, recent findings provide encouragement to further explore the potential of mitochondrial p53-based cancer therapeutics (1-3).
Inactivating mutations of the p53 gene are found in approximately half of all human cancers. In most of the remaining cancers that retain a wild-type (WT) p53, the p53 pathway is deactivated by an increase in its inhibitors, a reduction in its activators or by inactivation of downstream targets (1). In these cases, restoring WT p53 apoptotic function has been recognised as a promising strategy for cancer therapy. Hence, a detailed understanding of the mechanisms of regulation of p53-mediated apoptosis has been an important research objective with significant clinical impact (3).
One of the key enzymes involved in the regulation of WT p53 function is the protein kinase C (PKC). PKC is a family of serine/threonine kinases with at least 10 isoforms grouped into three major subfamilies according to their primary structure and cofactors required for activation: classical (α, βI, βII and γ), novel (δ, ε, η and θ) and atypical (ζ and λ\ι). PKC isoforms are important regulators of several cellular processes, such as cell proliferation and death, and a striking feature is that individual isoforms can exert either similar or opposite effects in these processes (4). In fact, several studies underscore a major role of PKC, particularly of PKCδ, in the regulation of p53 apoptotic activity. It was demonstrated that PKCδ leads to p53 accumulation and phosphorylation with consequent activation of a p53-mediated apoptosis (5-10).
However, due to the high complexity of the mammalian p53 pathway and PKC family, namely the coexistence of several PKC isoforms in the same cell, the discrimination of the role of PKC isoforms in the regulation of p53 apoptotic mechanisms, particularly of its transcription-dependent and -independent activity, is still uncertain. To address this issue, yeast cells co-expressing the human WT p53 and an individual mammalian PKC isoform of the classical (PKCα), novel (PKCδ and ε) and atypical (PKCζ) PKC subfamilies, and considered the isoforms most commonly involved in carcinogenesis, were used. In fact, using this yeast co-expression system, a differential modulation of p53-induced yeast growth inhibition and cell cycle arrest by distinct PKC isoforms was shown in our previous work (11) . Moreover, other authors have confirmed the versatility of the yeast cell model to study different aspects of p53 function (12) . For instance, a recent work showed that p53 could also function as a sequence-specific transcription factor in yeast. This study revealed several remarkable similarities between the transcription-dependent p53 activity in yeast and mammalian cells (13) .
With the yeast approach used, it was possible to ascertain the role of PKCα, δ, ε and ζ in the regulation of p53-mediated apoptosis. In contrast to PKCα and ζ, PKCδ and ε activated transcription-dependent and -independent p53 mechanisms that cooperated to ultimately cause an apoptotic cell death. This study therefore identified PKCδ and ε as major positive regulators of p53-mediated apoptosis, and consequently as promising therapeutic targets for cancer treatment. Another relevant point arising from this study was to provide the first evidence for the conservation in yeast of a transcription-dependent and -independent p53-mediated apoptosis, with the validation of the yeast cell model to further understand the regulation of these p53 apoptotic mechanisms.
